Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 7/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 2/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877153 | 0.93 | GRIN2B (0.40) | GRIN2BMAPTNPC1RAB9A | |
| SCHEMBL3928018 | 0.91 | GRIN2B (0.42) | GRIN2BALOX5APFEN1 | |
| SCHEMBL4877360 | 0.89 | KDM4E (0.37) | GRIN2BMAPTJAK2JAK1TYK2 | |
| SCHEMBL4875214 | 0.88 | KMT2A (0.33) | GRIN2BALOX5APFEN1MAPTJAK1 | |
| SCHEMBL4877234 | 0.87 | IRAK4 (0.31) | MAPTJAK2JAK1TYK2JAK3 | |
| SCHEMBL4877559 | 0.86 | TRPV4 (0.35) | MAPTJAK2JAK1TYK2JAK3 | |
| SCHEMBL4877156 | 0.86 | KCNH2 (0.36) | GRIN2BMAPTGRM5 | |
| SCHEMBL4870801 | 0.86 | CBX7 (0.39) | GRIN2BIRAK4 | |
| SCHEMBL4876725 | 0.84 | KMT2A (0.41) | GRIN2BMAPTRAB9A | |
| SCHEMBL4875677 | 0.83 | GRIN2B (0.34) | GRIN2BMAPTGRM5RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | GRIN2B 3420/4885ALOX5AP 3943/4885FEN1 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.